Scarica l'app Stockscreener
19.56
2.74%
0.56
Precedente Chiudi:
$19.00
Aprire:
$19.03
Volume 24 ore:
41,049
Relative Volume:
0.03
Capitalizzazione di mercato:
$100.28M
Reddito:
-
Utile/perdita netta:
$-7.12M
Rapporto P/E:
-25.40
EPS:
-0.77
Flusso di cassa netto:
$-6.82M
1 W Prestazione:
+7.08%
1M Prestazione:
+271.81%
6M Prestazione:
+3,094%
1 anno Prestazione:
+6,528%
Intervallo 1D:
$19.03
$20.00
Intervallo di 1 settimana:
$17.09
$21.18
Portata 52W:
$0.2739
$38.50
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Nome
Monopar Therapeutics Inc
Settore
Industria
Telefono
(847) 388-0349
Indirizzo
1000 SKOKIE BLVD SUITE 350, WILMETTE
Confronta MNPR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| MNPR | 19.52 | 100.28M | 0 | -7.12M | -6.82M | -0.77 |
| VRTX | 449.81 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.23 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 588.46 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.98 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.53 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-01-28 | Iniziato | ROTH Capital | Buy |
Monopar Therapeutics Inc Borsa (MNPR) Ultime notizie
(MNPR) Proactive Strategies - Stock Traders Daily
HC Wainwright Has Positive Estimate for MNPR FY2024 Earnings - MarketBeat
HC Wainwright Issues Positive Forecast for Monopar Therapeutics (NASDAQ:MNPR) Stock Price - MarketBeat
Monopar Therapeutics stock target lifted, buy rating on AstraZeneca deal By Investing.com - Investing.com UK
Monopar Therapeutics (NASDAQ:MNPR) Releases Financial Results for the Third Quarter 2024Monopar Therapeutics Inc. recently disclosed its financial results for the third quarter ending September 30, 2024, in a press release dated November 8, 2024. The - Defense World
MNPRMonopar Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
Monopar Therapeutics Inc Reports Q3 2024 GAAP EPS of -$0.37 and Net Loss of $1.3 Million - GuruFocus.com
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments - The Manila Times
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments - GlobeNewswire Inc.
Janus Henderson Group PLC Acquires New Stake in Monopar Therapeu - GuruFocus.com
RA Capital Management, L.P. Acquires New Stake in Monopar Therap - GuruFocus.com
Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock - The Manila Times
Insider Purchase: CFO Karthik Radhakrishnan Acquires Shares of M - GuruFocus.com
Monopar Therapeutics Closes $19.2 Million Stock Offering - TipRanks
Monopar Therapeutics drops 16%, prices $19M offering at $16.25 per share - MSN
(MNPR) Investment Analysis - Stock Traders Daily
Monopar Therapeutics announces public stock offering By Investing.com - Investing.com Nigeria
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock - The Manila Times
Monopar Therapeutics announces public stock offering - Investing.com
Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock - The Manila Times
Monopar Therapeutics Inc. (NASDAQ:MNPR) Sees Significant Drop in Short Interest - MarketBeat
Monopar Therapeutics Inc.'s (NASDAQ:MNPR) biggest owners are retail investors who got richer after stock soared 208% last week - Simply Wall St
Individual investors are Monopar Therapeutics Inc.'s (NASDAQ:MNPR) biggest owners and were rewarded after market cap rose by US$40m last week - Yahoo Finance
Monopar Therapeutics Skyrockets 400% on Licensing Deal - MSN
Wilmette startup's stock soars as it buys back the drug its founder made from Big Pharma - Crain's Chicago Business
Monopar Therapeutics (NASDAQ:MNPR) Shares Gap DownHere's What Happened - MarketBeat
What's Going On With Monopar Therapeutics Shares Friday? - Benzinga
Monopar Therapeutics Secures License for Wilson Disease Treatment - Yahoo Finance
Why Deckers Outdoor Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - Benzinga
MNPR,NTLA,CPRI,WDC,TSLA: Top 5 Trending Stocks TodayMonopar Therapeutics (NASDAQ:MNPR), Capri Holdings (NYSE:CPRI) - Benzinga
Monopar Therapeutics Inc. has entered into an agreement to acquire worldwide license to ALXN-18 from Alexion Pharmaceuticals, Inc. - Marketscreener.com
Health Care Down Amid Mixed Drug Developments -- Health Care Roundup - MarketWatch
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.33% - MSN
Viking Therapeutics stock soars on heels of Q3 beat - Yahoo Finance
Monopar Therapeutics (NASDAQ:MNPR) Hits New 52-Week HighStill a Buy? - MarketBeat
Monopar secures global license for Wilson disease drug - Investing.com
Monopar retrieves Wilson disease candidate from AstraZeneca's scrap heap - Fierce Biotech
CDC And Prevention Advisory Panel Backs Expanded Use Of Pfizer And Merck's Pneumococcal Vaccines - Yahoo Finance
Monopar Therapeutics, Energy Vault Holdings, FREYR Battery: 3 Stocks Retailers Are Most Bullish Thursday Afternoon - Barchart
Why Is Monopar Therapeutics Stock Surging Over 400% On Thursday?AstraZeneca (NASDAQ:AZN), Monopar Therapeutics (NASDAQ:MNPR) - Benzinga
Monopar Up 450%Were You On Board? - RTTNews
Monopar Therapeutics (MNPR) Shares Surge on Partnership with Ale - GuruFocus.com
Monopar (MNPR) Experiences Stock Boost After An Agreement - Stocks Telegraph
Monopar Shares Surge on AstraZeneca Licensing Deal -- Update - MarketWatch
Monopar stock soars to 52-week high, hits $8.75 - Investing.com
Monopar secures global license for Wilson disease drug By Investing.com - Investing.com South Africa
Monopar Shares Rise on AstraZeneca Licensing Deal - Marketscreener.com
Monopar stock climbs as it takes over Wilson disease drug candidate (NASDAQ:MNPR) - Seeking Alpha
Monopar Therapeutics Inc Announces Agreement with Alexion, AstraZeneca Rare Disease for Late-Stage Wilson Disease Drug Candidate - Marketscreener.com
Monopar stock soars to 52-week high, hits $8.75 By Investing.com - Investing.com UK
Oral Mucositis Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Swedish Orphan Biovitrum, Galera Therapeutics, EpicentRx, Galera Therapeutics, Inc., Soligenix - Barchart
Monopar Therapeutics Inc Azioni (MNPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Monopar Therapeutics Inc Azioni (MNPR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Cittadine Andrew | Chief Operating Officer |
Jun 20 '24 |
Buy |
0.74 |
20,508 |
15,254 |
186,132 |
| Cittadine Andrew | Chief Operating Officer |
Jun 18 '24 |
Buy |
0.86 |
12,000 |
10,320 |
165,624 |
| Cittadine Andrew | Chief Operating Officer |
Jun 14 '24 |
Buy |
0.93 |
12,000 |
11,176 |
141,624 |
| Cittadine Andrew | Chief Operating Officer |
Jun 13 '24 |
Buy |
0.91 |
12,000 |
10,920 |
129,624 |
| Cittadine Andrew | Chief Operating Officer |
Jun 17 '24 |
Buy |
0.90 |
12,000 |
10,799 |
153,624 |
| Cittadine Andrew | Chief Operating Officer |
Jun 04 '24 |
Buy |
0.78 |
12,000 |
9,360 |
117,624 |
| Cittadine Andrew | Chief Operating Officer |
Jun 03 '24 |
Buy |
0.76 |
12,000 |
9,120 |
105,624 |
| Cittadine Andrew | Chief Operating Officer |
May 31 '24 |
Buy |
0.64 |
12,000 |
7,732 |
93,624 |
| Cittadine Andrew | Chief Operating Officer |
May 30 '24 |
Buy |
0.64 |
12,000 |
7,676 |
81,624 |
| Cittadine Andrew | Chief Operating Officer |
May 29 '24 |
Buy |
0.64 |
12,000 |
7,643 |
69,624 |
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):